key: cord-0967410-58dpct54
authors: Kant, Sam; Azar, Antoine; Geetha, Duvuru
title: Antibody response to COVID-19 booster vaccine in rituximab treated patients with ANCA associated vasculitis
date: 2021-11-22
journal: Kidney Int
DOI: 10.1016/j.kint.2021.11.012
sha: 135a6c64d6fb527ac1b174e2a8a6dadc6ef5fea6
doc_id: 967410
cord_uid: 58dpct54

nan

The success of the coronavirus infectious disease 2019 (COVID-19) vaccine has been accompanied by challenges, which include suboptimal response in patients on immunosuppression. Although booster doses of the vaccine have led to an increment in number of patients (solid organ transplant recipients and patients with rheumatic disease) achieving an antibody response, a considerable proportion continue to demonstrate none. 1, 2 While it is known that administration of rituximab is associated with lower response to the initial vaccine series, 3 there is a paucity of data regarding its effect with respect to booster doses. 4 We looked to the ascertain the antibody response post booster vaccine doses in patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) on maintenance rituximab, who had no response to the initial vaccine series.

AAV patients attending the vasculitis clinic at Johns Hopkins on rituximab therapy were screened for a completion of vaccine series and associated negative antibody response between January 2021 and September 2021. Immunoglobulin G antibodies to spike protein S1 subunit of on SARS-CoV-2 were measured using ELISA at least 1 month post completion of vaccination series and booster doses. Clinical demographics and immunological data were retrieved after review of the electronic health record.

Fifteen patients with no demonstrable antibody response received a booster dose. B cell depletion was defined as absolute CD19 count of 0/mm 3 . This study was approved by the Johns Hopkins Institutional Review Board.

Of the 15 patients, 7 patients had a discernable antibody response to a booster dose (table 1). The 

Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: A case series

Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: A case series

Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): An investigatorinitiated, single-centre, open-label study

Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with anti-neutrophil cytoplasmic antibody vasculitis

Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination